// App-Quantinova.ai

OR15-1 : Efficacy and Safety of Once-Weekly Semaglutide Monotherapy versus Placebo in Subjects with Type 2 Diabetes (SUSTAIN 1)

Researchers

Presenter

  • Shin-ichi Harashima

Principal Investigators

  • George Tsoukas

  • Jeffrey Unger

  • Julie Derving Karsbol

  • Thomas Hansen

  • Stephen Bain

Medical Centers

  • Billings Clinic Cancer Center, Billings, MT

  • Kyoto University, Kyoto, Japan

  • Catalina Research Institute, Chino, CA

  • ABMU / Swansea University, Swansea, United Kingdom.

  • Montreal University, Montreal, QC, Canada

Locations

  • United States

  • Canada

  • Japan

  • United Kingdom

Companies

  • Novo Nordisk A/S

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

  • Genetic Disorder

Disease

  • Type 2 diabetes mellitus

Biomarkers

  • Hemoglobin A1c

Drug/Treatment

  • Semaglutide

Outcome

  • N/A

Study Design

  • randomized

  • double blind/blinded

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved